39.10USD-0.05%Mkt Cap: 2.78B USDP/E: —Last update: 2026-06-01
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap2.78B USD
Enterprise Value6.92B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-141.20M USD
Revenue/Share—
Last Price39.10 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees220
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-20.16
PEG—
EV/EBITDA-37.38
EV/Revenue—
P/S—
P/B1.84
EPS (TTM)-2.64
EPS (Forward)-1.95
52W Range
15.8029% of range94.90
52W High94.90 USD
52W Low15.80 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-9.31%
ROA-8.91%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-222.20M USD
CapEx (TTM)3.61M USD
FCF Margin—
FCF Yield-6.46%
Net Debt-1.44B USD
Net Debt/EBITDA7.78
Balance Sheet
Debt/Equity0.00
Current Ratio24.81
Quick Ratio24.43
Book Value/Sh21.41 USD
Cash/Share6.805 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)106.47 USD
Target Range69.50 USD – 145.00 USD
# Analysts16
Ownership
Shares Out.71.07M
Float164.18M
Insiders2.66%
Institutions96.03%
Short Interest
Short Ratio6.6d
Short % Float10.90%
Short % Out.7.95%
Shares Short5.65M
Short (prev mo.)6.15M
Technical
SMA 5045.37 (-13.8%)
SMA 20046.59 (-16.1%)
Beta-1.39
S&P 52W Chg27.94%
Avg Vol (30d)747.85K
Avg Vol (10d)647.52K
Technical Indicators
RSI (14)41.5
MACD-1.9594
MACD Signal-2.6562
MACD Hist.+0.6968
BB Upper42.81 USD
BB Middle39.18 USD
BB Lower35.56 USD
BB Width18.50%
ATR (14)2.234 USD
Vol Ratio (20d)0.39x